The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications.

This study is currently recruiting participants.

Verified by University of New Mexico, April 2008

Sponsored by:	University of New Mexico
Information provided by:	University of New Mexico
ClinicalTrials.gov Identifier:	NCT00656331

Purpose

The purpose of this study is to compare the effects of the cholesterol medication taken with each blood pressure medication alone on heart disease risk factors including blood pressure, cholesterol, inflammation, blood sugar control, blood vessal function, and other heart disease risk factors.

Condition	Intervention
Hypertension	Drug: Amlodipine and Hydrocholorothiazide

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Atorvastatin Atorvastatin calcium Hydrochlorothiazide Amlodipine Amlodipine besylate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications: A Comparison of Amlodipine and Hydrochlorothiazide

Further study details as provided by University of New Mexico:

Primary Outcome Measures:

PAI-1 [ Time Frame: study completion ] [ Designated as safety issue: No ]

Estimated Enrollment:	20
Study Start Date:	August 2005
Estimated Study Completion Date:	April 2010
Estimated Primary Completion Date:	April 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Active Comparator Amlodipine	Drug: Amlodipine and Hydrocholorothiazide Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide
2: Active Comparator HCTZ	Drug: Amlodipine and Hydrocholorothiazide Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

mild hypertension and high cholesterol

Exclusion Criteria:

diabetes and heart disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00656331

Contacts

Contact: Kathleen Colleran, MD

(505)272-4658

kcolleran@salud.unm.edu

Locations

United States, New Mexico
UNMHSC	Recruiting
Albuquerque, New Mexico, United States, 87131
Contact: Kathleen Colleran, MD 505-272-4658 kcolleran@salud.unm.edu

Sponsors and Collaborators

University of New Mexico

Investigators

Principal Investigator:

Kathleen Colleran, MD

University of New Mexico

More Information

Responsible Party:	University of New Mexico ( Kathleen Colleran )
Study ID Numbers:	05-106
Study First Received:	April 7, 2008
Last Updated:	April 7, 2008
ClinicalTrials.gov Identifier:	NCT00656331
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Calcium, Dietary
Vascular Diseases
Hydrochlorothiazide

Atorvastatin
Amlodipine
Hypertension

Additional relevant MeSH terms:

Antimetabolites
Vasodilator Agents
Molecular Mechanisms of Pharmacological Action
Antilipemic Agents
Calcium Channel Blockers
Enzyme Inhibitors
Cardiovascular Agents

Anticholesteremic Agents
Antihypertensive Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmacologic Actions
Membrane Transport Modulators
Therapeutic Uses
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 16, 2009